

# Using Conceptual Modeling to Plan and Execute Quasi-Experimental Studies - An Example from Hearing Loss

Annie N. Simpson and Kit N. Simpson

Department of Healthcare Leadership and Management


Department of Otolaryngology-Head and Neck Surgery

Medical University of South Carolina

Charleston, South Carolina


Work supported by  
NIH/NIDCD (US)

# A Statistical Model - A Mathematical Formulaic Model




# The Classical Medical Model - A Theoretical Framework

## THE MEDICAL MODEL OF DISABILITY





# An Alternative Framework

## THE SOCIAL MODEL OF DISABILITY



# Model: The International Classification of Functioning, Disability and Health (ICF)





# Differences between Theoretical Framework/Models and Conceptual Models?


# Conceptual Framework/Model

- This consists of concepts that are placed within a logical and sequential design
- Represents less formal structure and used for studies in which existing theory is inapplicable or insufficient
- Based on specific concepts and propositions, derived from empirical observation and intuition
- May deduce theories from a conceptual framework

## Purposes of Conceptual Framework

- To clarify concepts and propose relationships among the concepts in a study
- To provide a context for interpreting the study findings
- To explain observations
- To encourage theory development that is useful to practice

# Andersen Healthcare Utilization Model



Sources: Andersen RM, Davidson PL, Baumeister SE. Improving access to care in America. In: Kominski EF, editor. Changing the U.S. health care system: key issues in health services, policy, and management. 4th edition. San Francisco, CA: Jossey-Bass; 2013. p. 33–69.

Andersen, Ronald (1995). "Revisiting the behavioral model and access to medical care: does it matter?". *J Health Soc Behav.* **36** (1): 1–10. [doi:10.2307/2137284](https://doi.org/10.2307/2137284). [PMID 7738325](https://pubmed.ncbi.nlm.nih.gov/7738325/).

Aday, Lu Ann; Andersen R (1974). "A framework for the study of access to medical care". *Health Serv Res.* **9** (3): 208–20.




# Donabedian's Quality Improvement Model



Sources: Donabedian, A. (1988). "The quality of care: How can it be assessed?". *JAMA*. **260** (12): 1743–8.  
Donabedian, A (2005). "[Evaluating the quality of medical care. 1966](#)". *The Milbank quarterly*. **83** (4): 691–729.

# Adapted Conceptual Model Based on the EPIS Framework of Implementation and Dissemination



Sources: Aarons GA, Hurlburt M, Horwitz SM. Advancing a conceptual model of evidence-based practice implementation in public service sectors. Administration and policy in mental health. 2011;38(1):4-23. Epub 2011/01/05. doi: 10.1007/s10488-010-0327-7. PubMed PMID: 21197565; PMCID: Pmc3025110.

Aarons GA, Green AE, Willging CE, Ehrhart MG, Roesch SC, Hecht DB, Chaffin MJ. Mixed-method study of a conceptual model of evidence-based intervention sustainment across multiple public-sector service settings. Implement


### Most Common Chronic Conditions, by Age and Gender

	MALE	FEMALE
ALL AGES	<ul style="list-style-type: none"> <li>• Orthopedic impairments</li> <li>• Sinusitis</li> <li>• <b>Hearing impairments</b></li> <li>• Hypertension</li> <li>• Hay Fever</li> </ul>	<ul style="list-style-type: none"> <li>• Sinusitis</li> <li>• Arthritis</li> <li>• Orthopedic impairments</li> <li>• Hypertension</li> <li>• Hay Fever</li> </ul>
0–17	<ul style="list-style-type: none"> <li>• Asthma</li> <li>• Hay Fever</li> <li>• Sinusitis</li> <li>• Bronchitis</li> <li>• Dermatitis</li> </ul>	<ul style="list-style-type: none"> <li>• Sinusitis</li> <li>• Asthma</li> <li>• Hay Fever</li> <li>• Bronchitis</li> <li>• Dermatitis</li> </ul>
18–44	<ul style="list-style-type: none"> <li>• Orthopedic impairments</li> <li>• Sinusitis</li> <li>• Hay Fever</li> <li>• <b>Hearing impairments</b></li> <li>• Hypertension</li> </ul>	<ul style="list-style-type: none"> <li>• Sinusitis</li> <li>• Orthopedic impairments</li> <li>• Hay Fever</li> <li>• Migraine</li> <li>• Asthma</li> </ul>
45–74	<ul style="list-style-type: none"> <li>• Hypertension</li> <li>• Arthritis</li> <li>• <b>Hearing impairments</b></li> <li>• Orthopedic impairments</li> <li>• Heart Disease</li> </ul>	<ul style="list-style-type: none"> <li>• Arthritis</li> <li>• Hypertension</li> <li>• Sinusitis</li> <li>• Orthopedic impairments</li> <li>• Hay Fever</li> </ul>
75+	<ul style="list-style-type: none"> <li>• <b>Hearing impairments</b></li> <li>• Arthritis</li> <li>• Heart Disease</li> <li>• Hypertension</li> <li>• Cataracts</li> </ul>	<ul style="list-style-type: none"> <li>• Arthritis</li> <li>• Hypertension</li> <li>• <b>Hearing impairments</b></li> <li>• Heart Disease</li> <li>• Cataracts</li> </ul>

SOURCE: National Academy on an Aging Society analysis of National Health Interview Survey data.

- Hearing loss is one of the most common chronic health conditions, especially among older adults
- Affects ~360 million people worldwide
- Affects >60% of US adults over age 70
- Associated with decreased quality of life, and increased risk of hospitalization and functional and cognitive declines.
- Little is known about the impact of HL on healthcare use and cost

**Figure 1: Conceptual Model of the Effects of HL**



Simpson AN, Simpson KN, Dubno JR. Higher Health Care Costs in Middle-aged US Adults With Hearing Loss. *JAMA Otolaryngol Head Neck Surg* 2016;142:607-609.

# Study Design

- 2 cohorts of patients over age 65
- ICD-9 code of HL (V41.2, V72.1x, 388.00, 388.01, 388.40, 388.43, 388.44, 388.5, 389.1x, 389.2x)
- Baseline Matching based on 6 months of bills prior to index date
- Included only individuals
  - with at least 18 months of continuous insurance coverage
  - > 65 years of age
- Excluded individuals with diagnoses of late effects of stroke, coma or paralysis

# Defining “Cost” and Comparison Groups

- Healthcare bills (provider plus any out-of-pocket) up to 18-months post index were summed by patient to calculate total payments for:
  - \*inpatient
  - \*prescription medication
  - \*Outpatient
  - \*cost of hearing services (HS)
- Three Comparison Groups
  - Individuals with no hearing loss diagnosis
  - Individuals with hearing loss:
    - With Hearing Services were defined for bills with ICD-9 procedure codes 9548, 69710, 69711, V532, V5014, V5267, V5298, V5010, V5011, or V5275.
    - Without Hearing Services

## 2 Cohorts plus 1 Subgroup

- First cohort: Medicare plus Supplemental privately insured individuals (MS) was extracted using the 2009-2013 Market Scan<sup>®</sup> data base
- Second cohort: Medicare (M5%) extracted from the 2012-2013 Medicare Limited Data Set standard analytic files (SAF) National 5% sample, Medicare as primary insurance.
- Subgroup: Dually eligible (DE) Medicare/Medicaid. A subgroup of the Medicare group who were dually eligible for Medicaid.

# Table 1. Patient Descriptive Characteristics

	MS		M5%		DE	
	Hearing Loss (n= 391,108)	No Hearing Loss (n = 391,108)	Hearing Loss (n = 75,148)	No Hearing Loss (n = 75,148)	Hearing Loss (n = 8,729)	No Hearing Loss (n = 8,509)
Age, m(sd)	75.9 (7.8)	75.9 (7.8)	77.1 (8.0)	77.0 (7.9)	79.0 (8.2)	78.6 (8.1)
Charlson Score, m(sd)	0.1 (0.4)	0.1 (0.4)	0.2 (0.7)	0.1 (0.7)	0.3 (1.0)	0.2 (0.9)
Follow Up Days, m(sd)	540.0 (29.3)	537.5 (33.2)	191.1 (59.1)	195.2 (67.0)	199.5 (76.1)	203.7 (82.0)
Sex						
Male	192,038 (49.1)	194,133 (49.6)	29,221 (38.9)	29,265 (38.9)	2,343 (26.8)	2,298 (27.0)
Female	199,070 (50.9)	196,975 (50.4)	45,927 (61.1)	45,883 (61.1)	6,386 (73.2)	6,211 (73.0)
White Race	NA	NA	66,669 (88.7)	66,958 (89.1)	5,304 (60.8)	5,288 (62.2)
Hearing Services	109,968 (28.1)	0 (0.0)	2,873 (3.8)	0 (0.0)	262 (3.0)	0 (0.0)
Chronic Conditions						
Hypertension	51,411 (13.1)	48,711 (12.5)	47,346 (63.0)	47,647 (63.4)	6,506 (74.5)	6,339 (74.5)
Diabetes	21,520 (5.5)	20,538 (5.3)	20,147 (26.8)	20,222 (26.9)	3,398 (38.9)	3,238 (38.1)
CondHF	16,499 (4.2)	15,146 (3.9)	16,504 (22.0)	16,431 (21.9)	2,058 (23.6)	1,890 (22.2)
Heart Valve	8,802 (2.6)	7,737 (2.0)	8,364 (11.1)	8,051 (10.7)	1,005 (11.5)	905 (10.6)
COPD	8,522 (2.2)	7,561 (1.9)	7,958 (10.6)	8,016 (10.7)	1,405 (16.1)	1,335 (15.7)
CHF	4,195 (1.1)	3,518 (0.9)	5,545 (7.4)	5,237 (7.0)	1,229 (14.1)	1,034 (12.2)
PHD	1,024 (0.3)	845 (0.2)	1,551 (2.1)	1,366 (1.8)	178 (2.0)	153 (1.8)
Asthma	4,943 (1.3)	4,313 (1.1)	3,946 (5.3)	3,930 (5.2)	624 (7.2)	584 (6.9)
Diverticulitis	4,625 (1.2)	4,213 (1.1)	4,082 (5.4)	4,026 (5.4)	410 (4.7)	374 (4.4)
CRF	3,791 (1.0)	3,467 (0.9)	4,889 (6.5)	4,691 (6.2)	819 (9.4)	717 (8.4)
Dementia	2,827 (0.7)	2,473 (0.6)	4,428 (5.9)	4,250 (5.7)	1,254 (14.4)	1,103 (13.0)
RA	2,082 (0.5)	1,778 (0.5)	1,947 (2.6)	1,880 (2.5)	275 (3.2)	246 (2.9)
Carditis	1,909 (0.5)	1,550 (0.4)	1,829 (2.4)	1,702 (2.3)	222 (2.5)	187 (2.2)
Epilepsy	888 (0.2)	731 (0.2)	846 (1.1)	793 (1.1)	181 (2.1)	167 (2.0)
Parkinson's	833 (0.2)	700 (0.2)	902 (1.2)	897 (1.2)	167 (1.9)	148 (1.7)
SLE	688 (0.2)	620 (0.2)	633 (0.8)	602 (0.8)	55 (0.6)	53 (0.6)
Hepatitis	382 (0.1)	334 (0.1)	490 (0.7)	390 (0.5)	156 (1.8)	110 (1.3)
MS	193 (0.1)	174 (0.0)	84 (0.1)	81 (0.1)	9 (0.1)	5 (0.1)
Schizophrenia	104 (0.0)	82 (0.0)	192 (0.3)	153 (0.2)	113 (1.3)	93 (1.1)
HIV	62 (0.0)	43 (0.0)	46 (0.0)	35 (0.0)	13 (0.2)	13 (0.2)
CF	12 (0.0)	10 (0.0)	10 (0.0)	8 (0.0)	1 (0.0)	2 (0.0)
SCA	12 (0.0)	12 (0.0)	9 (0.0)	8 (0.0)	2 (0.0)	0 (0.0)



# Table 2. Adjusted 18-month Total Healthcare Payments by Hearing Loss<sup>†</sup>


	Adjusted Mean (95% Confidence Interval), \$		
	Hearing Loss	Hearing Loss with Hearing Services	No Hearing Loss
<b>MS*</b>	20,304 (20,211-20,398)	18,873 (18,735-19,012)	16,717 (16,652-16,782)
<b>M5%**</b>	11,957 (11,815-12,101)	10,309 (9,713-10,942)	8,178 (8,083-8,275)
<b>DE**</b>	16,281 (15,737-16,843)	12,850 (10,599-15,579)	11,624 (11,237-12,024)

\*Includes prescription payments; \*\*Payments do not include prescription medication.


<sup>†</sup>Estimates are adjusted for age, sex, race (when available), Charlson Score, HS use, time in study and 22 chronic conditions.

All p-values <0.001 within cohort.

**Comparison of Adjusted Mean Costs by Hearing Loss**  
(Point Estimate and 95% CI)




# Figure 1. Adjusted 18-month Total Healthcare Payments by Hearing Loss



# Principal Findings

- Study Goal: Compare the average healthcare costs in US older adults with and without hearing loss
- Multiple data sources enables us to examine health care cost for Medicare patients who have substantially different levels of financial resources
- After propensity score matching and covariate adjustment, we observed >20% higher payments over a 1.5-year time period for a group of insured patients with HL


**Figure 1: Conceptual Model of the Effects of HL**




**Unmeasured Confounders?**

1. Treatment Seeking Behavior
2. Frailty
3. Disease Severity

**Figure 1: Conceptual Model of the Effects of HL**



**Figure 1: Conceptual Model of the Effects of HL**



# Limitations

- This study is limited by:
  - The lack of audiometry confirmation of HL
  - Inability to differentiate between successful HL interventions and failed interventions
- Residual selection bias may remain due to unmeasured variables
- Billing data contain coding errors and variation
- Billing data contain limited clinical information

# Acknowledgements

This work was supported by grant R21 DC014031-01 from NIH/NIDCD and by the South Carolina Clinical and Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, through NIH Grant Numbers UL1 RR029882. This investigation was conducted in a facility constructed with support from NIH Research Facilities Improvement Program Grant Number C06 RR14516.

Medical University of South Carolina  
Departments of Healthcare Leadership and Management and  
Otolaryngology-Head and Neck Surgery





For more information contact Annie Simpson:

[simpsona@musc.edu](mailto:simpsona@musc.edu)

# Conclusions

- All three data sets defined by patients' insurance type;
  - patient with untreated HL had the highest cost, followed by patients with treated HL, with patients without HL have lowest cost
- MS cohort had the highest means cost (Drug Costs)
- M5% cohort had the lowest cost
- DE group (poorest patients), had consistently ↑costs across the HL categories, and marginal cost difference between the treated and the untreated HL group
  - Economic effect of untreated HL may be exacerbated by poverty

# Discussion and Policy Implications

- Findings consistent with earlier cost study in Adults 55-64 years of age (Simpson).
- Supported by study finding increased hospitalization risk in people with hearing loss (Genther).
- No Medicare coverage for hearing aids, nor for most hearing services
- Private insurance and Medicaid has limited hearing coverage
- Medicaid coverage varies widely by state

# Procedure Codes for Hearing Services

- 9548 - Fitting of Hearing Aid
- 69710 - Surgical Procedures on the Middle Ear
- 69711 - Other Procedures on the Middle Ear
- V532 - Adjustment Hearing Aid
- V5014 - Repair/Modification Hearing Aid
- V5267 - Hearing aid or assistive listening device/supplies/accessories
- V5298 - Hearing Aid not otherwise classified
- V5010 - Assessment for Hearing Aid
- V5011 - Fitting/orientation/checking of hearing aid
- V5275 - Ear impression

# Diagnosis Codes for Hearing Loss

- V41.2 - Problems with hearing
- V72.1x - Examination of Ears and Hearing

## 388 Other Disorders of the Ear

- 388.00 - Degenerative and vascular disorders
- 388.01 - Presbycusis
- 388.40 - Abnormal Auditory Perception
- 388.43 - Impairment of Auditory Discrimination
- 388.44 - Auditory Recruitment
- 388.5 - Disorders of Acoustic Nerve

## 389 Hearing Loss

- 389.1x - Sensorineural Hearing Loss
- 389.2x - Mixed conductive and sensorineural hearing loss